EMVision Medical Devices Limited (ASX: EMV) has released its Appendix 4C quarterly activities and cashflow report for the period ended 30 June 2026, confirming the company's Pivotal (Validation) Trial for its emu™ point-of-care brain scanner has surpassed key enrolment milestones across training and primary analysis cohorts. The company also confirmed it received $2.0 million in non-dilutive grant funding during the quarter and maintained a strong cash balance of $17.1 million as at 30 June 2026. EMVision is now preparing to add an acute ischaemia detection endpoint to the Pivotal Trial, a move the company says could materially expand the emu™ device's clinical utility and commercial value proposition from its first product release. Investors are watching closely as the company progresses toward a planned FDA De Novo clearance submission and the anticipated launch of the emu™ Regional Benefits Study in the second half of calendar year 2026.

Key Points

  • EMVision Medical Devices Limited (ASX: EMV) is an Australian medical device company developing portable neurodiagnostic brain scanners, including the emu™ bedside device and the First Responder pre-hospital device.
  • The Pivotal (Validation) Trial for the emu™ brain scanner has surpassed key enrolment milestones, with full enrolment expected from late CY2026 or early CY2027.
  • The company received $2.0 million in non-dilutive grant funding during the quarter and held $17.1 million in cash as at 30 June 2026, with $4.6 million in further non-dilutive funding remaining under current grant programs.
  • Investors should watch for the planned FDA pre-submission (Q-Sub) meeting regarding the proposed acute ischaemia detection endpoint, completion of the First Responder Mobile Stroke Unit Study Stage 1, and the launch of the emu™ Regional Benefits Study in 2H CY26.

How EMVision's emu™ Pivotal Trial Is Building Momentum Toward FDA De Novo Clearance

EMVision Medical Devices continued to advance its Pivotal (Validation) Trial during the June 2026 quarter, with recruitment now past key enrolment milestones across both the training and primary analysis cohorts. The company reported that recruitment momentum continues to build across all active United States and Australian hospital sites, supported by acceleration initiatives introduced during the quarter. Importantly, the company noted that no device-related adverse events have been reported to date, and that the emu™ device continues to integrate seamlessly into hospital code stroke workflows — a clinically significant outcome for a portable diagnostic device operating in high-pressure emergency settings.

The Pivotal (Validation) Trial is structured as a multi-centre, prospective, blinded diagnostic performance study, specifically designed to support FDA De Novo clearance for EMVision's first-generation commercial product. The primary objective of the trial is to demonstrate haemorrhage detection sensitivity and specificity of greater than 80%. EMVision noted that it remains blinded to certain study data until recruitment is completed and data is independently analysed. The company also confirmed that data is being collected in a manner that allows validation and read-outs of additional diagnostic features without the need to undertake a supplementary full validation trial. Trial ramp-up, protocol enhancements, and active FDA engagement are all cited as supporting a path to full enrolment from late CY2026 or early CY2027, with sequential cohort readouts to follow shortly thereafter.

The Eight Leading Hospital Sites Currently Recruiting Patients Into EMVision's Pivotal Trial

The breadth and prestige of clinical sites participating in EMVision's Pivotal (Validation) Trial reflects the growing institutional interest in the company's emu™ technology. Current recruiting sites include Mayo Clinic in Jacksonville, Florida; Mt Sinai Hospital and Mt Sinai West in New York; Ronald Reagan UCLA Medical Center in California; Memorial Hermann at both the Texas Medical Centre and Memorial City locations in Texas; Royal Melbourne Hospital in Victoria, Australia; and Liverpool Hospital in New South Wales, Australia. These are among the most prominent academic, tertiary, and teaching hospitals in both the United States and Australia, lending significant credibility to the trial data being generated.

EMVision also confirmed that Princess Alexandra Hospital, which had previously participated in the company's Continuous Innovation Study, is now transitioning into the Pivotal (Validation) Trial. The company noted this transition leverages existing site readiness, trained staff, and clinical familiarity with the technology, which may help accelerate enrolment at that site. Additionally, EMVision stated it is in advanced preparations to onboard further leading US academic medical centres that have been referred to the company, which the announcement suggests reflects growing clinical interest in both the trial and the underlying emu™ technology platform more broadly.

EMVision's Plan to Add Acute Ischaemia Detection to the emu™ Pivotal Trial and What It Means Commercially

One of the most significant developments disclosed in the June 2026 quarterly update is EMVision's preparation to add an acute ischaemia detection endpoint to the Pivotal (Validation) Trial. This follows what the company described as significant progress on the feature's development through the Continuous Innovation Study. Because ischaemic stroke patients are already being enrolled in the Pivotal Trial, the company stated that any modifications are expected to be incremental, leveraging data already collected and existing workflow integrations. This could involve minor adjustments to the required sample size to ensure the ischaemic sub-cohort meets statistical objectives.

EMVision intends to engage with the FDA through an upcoming pre-submission meeting — known as a Q-Sub — covering the proposed clinical claims and performance thresholds for ischaemia detection. The company stated that validation of an ischaemia detection feature is expected to strengthen the emu™ device's clinical and commercial value proposition significantly. It noted that because stroke interventions are highly time-dependent, the ability to rapidly detect and classify both haemorrhagic and ischaemic stroke types in a single scan has the potential to reduce intervention delays and improve patient outcomes. The company further noted that successful validation of both capabilities in the initial commercial product has the potential to materially expand clinical utility from launch and further differentiate EMVision from other point-of-care technologies in the market.

How the Continuous Innovation Study Supports the emu™ AI Platform and Future Device Development

Alongside the Pivotal Trial, EMVision continued to progress its emu™ Continuous Innovation Study during the quarter. The company described this study as a strategic complement to the Pivotal Trial, with its primary purpose being the generation of proprietary datasets from suspected stroke and traumatic brain injury patients. These datasets are used to support AI model refinement and feature development, strengthening EMVision's competitive positioning and facilitating ongoing platform development. Key features being developed include acute ischaemia and large vessel occlusion detection — both of which are clinically important in the context of emergency stroke care.

The clinical footprint of the Continuous Innovation Study continued to evolve during the quarter, with Box Hill Hospital joining the study in place of Princess Alexandra Hospital, which transitioned into the Pivotal Trial. The company also confirmed that additional site activations are underway to enable efficient clinical data generation going forward. The ongoing generation of proprietary clinical data through this study is a key part of EMVision's strategy to maintain a defensible competitive position in the point-of-care neurodiagnostics space, particularly as the company prepares its first-generation emu™ product for commercialisation.

Royal Flying Doctor Service Aeromedical Study Confirms Real-World Feasibility of the First Responder Device

EMVision also disclosed the completion of a First Responder aeromedical feasibility and usability study conducted in partnership with the Royal Flying Doctor Service (RFDS) during the quarter. The company reported that flight nurses and patients rated the prototype device favourably in real-world operation, representing a meaningful milestone for the pre-hospital application of EMVision's technology. Conducting a usability study in the aeromedical environment is a particularly demanding test for any portable medical device, given the operational constraints of flight, including space limitations, vibration, and the clinical demands placed on flight nursing staff.

The First Responder device is described by EMVision as an ultra-lightweight pre-hospital brain scanner, intended for use by first responders in settings outside the hospital environment. The successful completion of this feasibility and usability study with the RFDS is an important proof-of-concept step for EMVision as it develops the First Responder platform. The company also noted that the acute ischaemia data being generated through the emu™ Pivotal Trial will help build the clinical and regulatory foundation for the First Responder device in pre-hospital settings — illustrating how the two development programs are designed to inform and reinforce each other.

First Responder Mobile Stroke Unit Study Stage 1 Nearing Completion Ahead of Reporting

Separate from the RFDS aeromedical study, EMVision's First Responder Mobile Stroke Unit Study Stage 1 was disclosed as nearing completion and reporting as at the end of the June 2026 quarter. While the company did not provide detailed findings from this study in the quarterly update, the announcement indicates it is at an advanced stage. Mobile stroke units represent a specific and growing category of pre-hospital stroke care infrastructure, and the inclusion of the First Responder device in this study context speaks to the breadth of deployment environments EMVision is targeting with its pre-hospital technology.

The upcoming reporting of Stage 1 results will be a key milestone for investors watching the development of EMVision's pre-hospital product pipeline. The results of both the RFDS aeromedical study and the Mobile Stroke Unit Study Stage 1 collectively begin to build the evidence base required to support regulatory submissions and eventual commercialisation of the First Responder device. EMVision has previously indicated that its second planned indication — traumatic brain injury — is also intended to be addressed by the First Responder platform over time, further extending the potential addressable market for this product.

emu™ Regional Benefits Study Progressing Toward 2H CY26 Launch in Partnership With Australian Stroke Alliance

EMVision confirmed that the CRC-P grant-funded emu™ Regional Benefits Study is progressing toward a launch in the second half of calendar year 2026. The study is being conducted in partnership with the Australian Stroke Alliance, Titan Pre-Hospital Innovation, and South Australia's Rural Support Service. Site selection was described as being at an advanced stage, and workstreams across protocol development, hospital deployment, and telehealth integration were reported as being on track. The study is designed to demonstrate the real-world benefits of the emu™ brain scanner in regional hospitals — a setting where access to advanced neuroimaging is often limited compared to major metropolitan centres.

During the quarter, EMVision met applicable milestones under the CRC-P grant program and received a further $0.4 million non-dilutive instalment as a result. The Regional Benefits Study is significant not only as a clinical initiative but also as a commercial positioning effort, helping to build the real-world evidence base that hospital procurement teams, health insurers, and health technology assessment bodies typically require before adopting new medical devices at scale. Regional and rural hospitals represent a substantial potential market for portable, point-of-care brain scanning technology given the logistical and workforce challenges these facilities face in providing rapid stroke diagnosis.

EMVision's $17.1 Million Cash Position and $2.0 Million in Non-Dilutive Grant Funding Received During the Quarter

EMVision reported a strong balance sheet position as at 30 June 2026, with cash reserves of $17.1 million. During the June quarter, the company received a total of $2.0 million in non-dilutive grant funding, comprising three separate payments: a $1.17 million Industry Growth Program payment, a $0.4 million CRC-P grant payment, and a $0.4 million final payment from the Australian Stroke Alliance. The company confirmed that these payments were triggered by grant funding milestones being met during the quarter, which means they reflect achieved program deliverables rather than unconditional receipts.

In addition to its current cash holdings, EMVision disclosed that $4.6 million in non-dilutive funding remains available under its current grant programs, providing further runway beyond the existing $17.1 million cash balance. Non-dilutive funding is particularly meaningful for pre-revenue medical device companies such as EMVision because it supports ongoing operations and clinical programs without requiring the issue of new equity to existing shareholders. The combination of a well-funded balance sheet and continued grant receipts positions the company to continue advancing its clinical programs through the critical period leading up to anticipated FDA De Novo clearance. The company did not provide specific forward-looking cash flow guidance for the September 2026 quarter in the announcement.

EMVision's Business Model, Stroke Market Opportunity, and the Key Risk Facing the Company

EMVision Medical Devices is an Australian company focused on developing and commercialising portable neurodiagnostic technology. The company's two primary products are the emu™ bedside brain scanner — which uses non-ionising radiofrequency technology rather than radiation — and the ultra-lightweight First Responder pre-hospital device. EMVision's first target clinical indication is acute stroke care, with a second planned indication in traumatic brain injury. The company's commercial model is centred on obtaining regulatory clearance through the FDA's De Novo pathway, which would allow it to market the emu™ as a novel, low-to-moderate risk medical device in the United States — the world's largest medical device market — before pursuing commercialisation in other geographies including Australia.

Stroke and traumatic brain injury impose substantial societal and health economic burdens globally, and portable brain scanners have the potential to address a critical unmet clinical need by enabling timely triage, transfer, and treatment decisions at the bedside or in pre-hospital settings. However, investors should be aware that EMVision remains a pre-revenue company at this stage, and that the path from clinical trial to regulatory clearance to commercial revenue involves significant regulatory, clinical, and execution risk. The company has not yet received FDA De Novo clearance, and there is no guarantee that the Pivotal Trial will meet its primary endpoints or that the FDA will grant clearance on the anticipated timeline. Delays to trial enrolment, unexpected regulatory feedback, or failure to demonstrate the required diagnostic performance thresholds would materially impact the company's commercialisation plans.